| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Laboratory of Immunology, Korea Research Institute of Bioscience and Biotechnology, Yusong, Taejon 305-333, Republic of Korea [D. C., H. S., Y. M. K., D. Y., K. H. P., I. C.]; Department of Dermatology, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul 134-701, Republic of Korea [D. H.]; Department of Anatomy, Inje University College of Medicine, Pusan 614-735, Republic of Korea [D. Y. H.]; Department of Dermatology, Holy Family Hospital, College of Medicine, The Catholic University of Korea, Pucheon 422-717, Republic of Korea [H. P.]; Department of Anatomy, Seoul National University, Seoul 110-799, Republic of Korea [W. J. L.]; Department of Biochemistry, College of Natural Sciences, Chungnam National University, Taejon 305-764, Republic of Korea [H. S., Y. S. K.]; Fujisaki Institute, Hayashibara Biochemical Laboratories, Okayama, Japan [M. K.]; Department of Microbiology and Immunology, Finch University of Health Science/The Chicago Medical School, Illinois 60064, [Y. B. K.]
It has been known that melanoma cells can suppress the immune system by
the Fas ligand. The present study investigated whether interleukin
(IL)-18, which can enhance Fas ligand expression, is produced by B16F10
melanoma cells and is involved in immune escape of tumor cells.
Immunohistology, reverse transcription-PCR, intracellular
fluorescence-activated cell-sorting analysis, and immunoblotting
demonstrated that melanoma cells express IL-18. C57BL/6 splenocytes
cultured with culture supernatants of B16F10 melanoma cells enhanced
IFN-
production, which was blocked by anti-IL-18 antibody,
indicating that IL-18 in the culture supernatants is functional. In
addition to IL-18, the IL-18 receptor was also detected in B16F10
melanoma cells, suggesting a role of this cytokine in regulating the
functions of B16F10 melanoma cells. The functional effect of IL-18 on
B16F10 melanoma cells was shown by reduction of Fas ligand expression
in cells treated with anti-IL-18 antibody or transfected with IL-18
antisense cDNA. In addition, the same treatments decreased
intracellular reactive oxygen intermediate levels in B16F10 melanoma
cells, indicating that IL-18 regulates reactive oxygen intermediate
production, which is involved in Fas ligand expression. Furthermore,
transfection of IL-18 antisense cDNA into melanoma cells increased the
susceptibility of tumor cells to natural killer cells in
vitro. When IL-18 antisense transfectants were implanted into
syngeneic mice, severe reduction of tumor cell growth was observed with
concomitant infiltrated natural killer cells in the tumor area. Taken
together, these results demonstrate that IL-18 has a critical role as a
survival factor for B16F10 melanoma cells.
This article has been cited by other articles:
![]() |
Q. Cao, W. Cai, G. Niu, L. He, and X. Chen Multimodality Imaging of IL-18-Binding Protein-Fc Therapy of Experimental Lung Metastasis Clin. Cancer Res., October 1, 2008; 14(19): 6137 - 6145. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kim, Y. Shao, S. Y. Kim, S. Kim, H. K. Song, J. H. Jeon, H. W. Suh, J. W. Chung, S. R. Yoon, Y. S. Kim, et al. Hypoxia-induced IL-18 Increases Hypoxia-inducible Factor-1{alpha} Expression through a Rac1-dependent NF-{kappa}B Pathway Mol. Biol. Cell, February 1, 2008; 19(2): 433 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nadif, M. Mintz, J. Marzec, A. Jedlicka, F. Kauffmann, and S. R. Kleeberger IL18 and IL18R1 polymorphisms, lung CT and fibrosis: a longitudinal study in coal miners Eur. Respir. J., December 1, 2006; 28(6): 1100 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mendoza, M. Valcarcel, T. Carrascal, E. Egilegor, C. Salado, B. K. L. Sim, and F. Vidal-Vanaclocha Inhibition of Cytokine-Induced Microvascular Arrest of Tumor Cells by Recombinant Endostatin Prevents Experimental Hepatic Melanoma Metastasis Cancer Res., January 1, 2004; 64(1): 304 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gutzmer, K. Langer, S. Mommert, M. Wittmann, A. Kapp, and T. Werfel Human Dendritic Cells Express the IL-18R and Are Chemoattracted to IL-18 J. Immunol., December 15, 2003; 171(12): 6363 - 6371. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakamori, M. Iwahashi, M. Nakamura, K. Ueda, X. Zhang, and H. Yamaue Intensification of Antitumor Effect by T Helper 1-dominant Adoptive Immunogene Therapy for Advanced Orthotopic Colon Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2357 - 2365. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Carrascal, L. Mendoza, M. Valcarcel, C. Salado, E. Egilegor, N. Telleria, F. Vidal-Vanaclocha, and C. A. Dinarello Interleukin-18 Binding Protein Reduces B16 Melanoma Hepatic Metastasis by Neutralizing Adhesiveness and Growth Factors of Sinusoidal Endothelium Cancer Res., January 15, 2003; 63(2): 491 - 497. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |